Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SC01009 for idiopathic pulmonary fibrosis
CTR20252778Phase 2Active
- Sponsor
- Zhejiang Shengchuang Precision Medical Technology
- Start
- Nov 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SC01009 in idiopathic pulmonary fibrosis (IPF), sponsored by Zhejiang Shengchuang Precision Medical Technology. Started Nov 2025; status: active.
02
Drugs
SC01009
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20252778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252778.